Pyxis Oncology Announces Preclinical Data on Anti-Siglec-15 BSI-060T (PYX-106) Presented by Biosion, Inc. at the 2022 American Association for Cancer Research (AACR) Annual Meeting
April 08 2022 - 1:05PM
Pyxis Oncology, Inc. (Nasdaq: PYXS) today announced preclinical
data supporting the potential of anti-Siglec-15 BSI-060T (now
PYX-106) presented by Biosion, Inc. at the 2022 American
Association for Cancer Research (AACR) Annual Meeting, taking place
in New Orleans, Louisiana, April 8-13, 2022.
“While immunotherapies hold immense potential to
improve the lives of patients with cancer, current therapeutics
have demonstrated success in only a narrow range of tumor types,”
said Ronald Herbst, Ph.D., Chief Scientific Officer of Pyxis
Oncology. “We believe that the key to improving response rates is
targeting novel pathways involved in immune suppression. The data
from this presentation strongly support that PYX-106 may be an
effective weapon in the otherwise limited arsenal of checkpoint
inhibitors. We look forward to working with Biosion and advancing
PYX-106 to the clinic and to patients in need.”
Hugh M. Davis, Ph.D., Chief Operating Officer,
Biosion, Inc. and President, Biosion USA, Inc. added, “These data
provide clear support for the potential of PYX-106 and highlight
its differentiated activity profile. We believe that its high
binding affinity together with its ability to overcome
Siglec-15-mediated T cell inhibition are critical for inducing a
robust anti-tumor immune response. Additionally, its long
half-life, as demonstrated in our non-human primate studies,
suggests that PYX-106 could provide extended coverage of the
target, which will be important for driving responses as a single
agent and in combination with other modalities, including other
immune-therapies.”
Presentation Details:
Title: BSI-060T, a high affinity,
fully human anti-Siglec-15 antibody as an alternative immune
checkpoint blockerAbstract #: 5522
Key findings from the presentation
include:
- PYX-106 binds to Siglec-15 with high affinity and blocks the
interaction between Siglec-15 and its putative receptor in
vitro
- PYX-106 shows cross-reactivity to monkey and mouse Siglec-15 in
vitro
- In ex vivo T cell response assays, PYX-106 relieves
Siglec-15-mediated inhibition of CD8+ and CD4+ T cell
proliferation and interferon-γ release
- In a humanized Siglec-15 mouse syngeneic tumor model, PYX-106
shows significant inhibition of tumor growth and was
well-tolerated
- PYX-106 also exhibits excellent pharmacokinetics in a non-human
primate study
The presentation will be made available on Pyxis
Oncology’s website, www.pyxisoncology.com.
About PYX-106PYX-106 is a fully
humanized monoclonal antibody designed to target a Siglec-15, an
immune suppressor that is broadly expressed across different tumor
types and macrophages. Siglec-15 and PD-L1 have limited overlap,
suggesting that PYX-106 could address PD-1/PD-L1 non-responders
across various tumor types and may be integral in combination with
other immunotherapies.
About Pyxis Oncology, Inc. Pyxis
Oncology, Inc. is a multi-asset, multi-modality company focused on
defeating difficult to treat cancers and improve patient lives. By
leveraging our fully integrated research, development and
commercial capabilities, our expert team is efficiently building a
diversified portfolio of next-generation therapeutics. Pyxis
Oncology’s therapeutic candidates are designed to directly kill
tumor cells, and to address the underlying pathologies created by
cancer that enable its uncontrollable proliferation and immune
evasion. Since its launch in 2019, Pyxis Oncology has developed a
broad portfolio of novel antibody drug conjugate, or ADC, product
candidates, and monoclonal antibody, or mAb, preclinical discovery
programs that it is developing as monotherapies and in combination
with other therapies. To learn more about Pyxis Oncology visit
www.pyxisoncology.com.
About Biosion, Inc.Biosion is a
global R&D biotechnology company committed to developing
antibody-based therapies to improve patient outcomes for the
treatment of immune and oncologic diseases. Established in 2017,
Biosion has built a pipeline of innovative biologics through its
internally derived technologies including the H³ antibody
discovery, SynTracer™ HT-endocytosis and Flexibody™ bispecific
platforms. Biosion has operations in the US, Australia, and China.
To learn more about Biosion visit www.biosion.com.
Forward-Looking StatementsThis
press release contains forward-looking statements for the purposes
of the safe harbor provisions under The Private Securities
Litigation Reform Act of 1995 and other federal securities laws.
These statements are often identified by the use of words such as
“anticipate,” “aim,” “believe,” “can,” “continue,” “could,”
“estimate,” “expect,” “intend,” “likely,” “may,” “might,”
“objective,” “ongoing,” “plan,” “potential,” “predict,” “project,”
“should,” “to be,” “will,” “would,” or the negative or plural of
these words, or similar expressions or variations, although not all
forward-looking statements contain these words. We cannot assure
you that the events and circumstances reflected in the
forward-looking statements will be achieved or occur and actual
results could differ materially from those expressed or implied by
these forward-looking statements. Factors that could cause or
contribute to such differences include, but are not limited to,
those identified herein, and those discussed in the section titled
“Risk Factors” set forth in the Company's most recent Annual Report
on Form 10-Q and in our other filings with the SEC. These risks are
not exhaustive. New risk factors emerge from time to time, and it
is not possible for our management to predict all risk factors, nor
can we assess the impact of all factors on our business or the
extent to which any factor, or combination of factors, may cause
actual results to differ materially from those contained in any
forward-looking statements. In addition, statements that “we
believe” and similar statements reflect our beliefs and opinions on
the relevant subject. These statements are based upon information
available to us as of the date of this press release, and while we
believe such information forms a reasonable basis for such
statements, such information may be limited or incomplete, and our
statements should not be read to indicate that we have conducted an
exhaustive inquiry into, or review of, all potentially available
relevant information. These statements are inherently uncertain,
and investors are cautioned not to unduly rely upon these
statements. Except as required by law, we undertake no obligation
to update any forward-looking statements to reflect events or
circumstances after the date of such statements.
Pyxis Oncology Contact:Courtney
DuganVice President, Head of Investor Relations & Corporate
Communications(617) 500-8872ir@pyxisoncology.com
Biosion USA Contact:Frank Liu,
Ph.D.Senior Director, Business Development(302)
998-5126frank.liu@biosion.com
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pyxis Oncology (NASDAQ:PYXS)
Historical Stock Chart
From Sep 2023 to Sep 2024